Coherus secures toripalimab rights for US and Canada
04-02-2021
AVNphotolab / iStockphoto.com
Coherus BioSciences has asked a court to dismiss patent infringement allegations brought against it by Amgen.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Coherus BioSciences, Amgen, Neulasta, BPCIA, FDA, biosimilar, patent, patent infringement
